八制自身免疫_(dá)第1頁(yè)
八制自身免疫_(dá)第2頁(yè)
八制自身免疫_(dá)第3頁(yè)
八制自身免疫_(dá)第4頁(yè)
八制自身免疫_(dá)第5頁(yè)
已閱讀5頁(yè),還剩72頁(yè)未讀, 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

八制自身免疫第1頁(yè)/共77頁(yè)RheumaticfeverisanimmunologicalinflammatorydiseasefollowsinfectionwithcertainstrainsofgroupAstreptococcieasilyrecurwithoutprophylaxiscarditischoreamigratorypolyarthritissubcutaneousnodulespermanentvalvulardiseaseerythemamarginatum第2頁(yè)/共77頁(yè)

Epidemiology

incidence:22/100000

inChina

season:winterorspringage:5–15y第3頁(yè)/共77頁(yè)北京兒童醫(yī)院1477名風(fēng)濕熱住院患者年齡分布約90%患者為>7歲兒童第4頁(yè)/共77頁(yè)Etiology☆

anonsuppurativecomplicationofgroupAstreptococcalinfectionoftheupperrespiratorytract☆

occurs1-4weeksafterconvalescenceofinfection☆

individualpropensity☆

environmentalfactorslatitudealtitudehumiditynutritioncrowdingage第5頁(yè)/共77頁(yè)P(yáng)athogenesismolecularmimicryofbacterialantigenssimilaritybetweenbacterialandselfmoleculesasrecognizedbyimmunecellsleadingtoacross-reactwithtargetorgansinthebodycirculatingimmunecomplexes(CIC)

circulatingimmunecomplexesactivatethecomplementsystemleadingtotheinflammatorychangesGeneticpronenessHLA-B35、HLA-DR4第6頁(yè)/共77頁(yè)capsule(synovialmembranes)Cellwallprotein(myocardium,endocardium)Cellwallpolysaccharides(myocardium,endocardium)

cellmembraneprotein

(myocardium

、subthalamicnucleus、caudatenucleus)TheantigensofGroupAstreptococciandmolecularmimicry第7頁(yè)/共77頁(yè)

pathology

急性滲出期(acuteexudativeperiod)增生期(proliferativeperiod)硬化期(scleroticperiod)

1

month3~4months2~3monthsconnectivetissueedemas,effuse,anddegenerate,infiltratedwithinflammatorycells.

Aschoffbodyinmyocardium,muscle,endocardium,subcutaneoustissuecollagenfiberhyperplasiaandscartissueformationmitral>aortic>tricuspid>pulmonary第8頁(yè)/共77頁(yè)acuteexudativeperiodedemaanddegenerationofcollagenandexudation

inpericardiumpericardialeffusionfibrinouspericarditis第9頁(yè)/共77頁(yè)proliferativeperiod

Aschoffbodyinendocardium中心:fibrinoidnecrosisofcollagen

外周:lymphocytes,plasmacellsandAschoffgiantcellsAschoffgiantcelllargecellswithtwoormorepalenucleithathaveprominentnucleoli.

第10頁(yè)/共77頁(yè)scleroticperiodmitralvalveshowsthickeningdistortedcusps,adherentcommissureswithcalcificationandthrombusdeposition,fusionandshorteningofchordaetendinae.stenoticmitralvalveshowsfusionofcommissures,missuresarefused;cuspsareseverelythickened.Thevalveisbothincompetentandstenotic.第11頁(yè)/共77頁(yè)ClinicalManifestationMajorclinicalmanifestations:

carditis;polyarthritis;chorea;subcutancousnodules;erythemamarginatumOrdinarycomplaints:

fever/arthralgia

Durationofacuterheumaticfever:

≤6months第12頁(yè)/共77頁(yè)

rheumaticcarditisIncidence:

40~50%OneandonlypermanentdamageEndocarditisMyocarditisPericarditis

Congestiveheartfailureduringtheinitialepisode:

5%~10%Pancarditis第13頁(yè)/共77頁(yè)MyocarditisTachycardiadisproportionatetothefeverCongestiveheartfailureGalloprhythmSoftsystolicmurmurheardattheapexECGabnormalitis:arrhythmias;prolongationoftheP-Rinterval;atrioventricularblock(AVB)

Cardiomegalyonx-rayBeforetreatment

aftertreatment

第14頁(yè)/共77頁(yè)

EndocarditisMitralregurgitation:

ApicalsystolicmurmurattheapexRelativemitralstenosis:

Low-pitchedmid-diastolicrumbleAorticregurgitation:

Diastolicmurmurinthethirdcostaattheleftsideofthesternum第15頁(yè)/共77頁(yè)

PericarditisPrecordialpainPericardialeffusion

Africtionrub

pericardialtamponade

hypotension;muffledheartsounds;jugularvenousdistensionStrikingincreaseinheartsizeonX-rayEchocardiography:pericardialeffusion>50ml第16頁(yè)/共77頁(yè)RheumaticarthritisIncidence:

50%~60%

Acutemigratorypolyarthritis

Largerjointsoftheextremitiesareaffected:

knee、ankle、elbow、wrist

Red,hot,swollen,exquisitelytender

andpainfulifmoved

asonejointrecovered,anotherjointmaybeinvolved

arthritislastslessthan1monthwithoutdeformity第17頁(yè)/共77頁(yè)ChoreaIncidence:3%~10%Female>male;8~12

yeasoldSudden,aimless,irregularmovementsoftheextremitiesandfacialmusclesthatsubsideduringsleepandexaggeratedbyemotionsEmotionalinstability:nervousMuscleweaknessandataxia:

clumsy,stumble,handwritingorspeechdisorders第18頁(yè)/共77頁(yè)erythemamarginatum

Thecharacteristicrashesconsistofanevanescent,pink,erythematousmaculae,withaclearcenterandserpiginousoutline.Therashistransient,migratoryandnonpruritic,whichfoundprimarilyonthetrunkandproximalextremities.第19頁(yè)/共77頁(yè)subcutaneousnodules

Subcutaneousnodulesarepainlesssmallswellings

overbonyprominences,primarilyovertheextensortendonsofthehands,feet,elbows,scalp,scapulae,andvertebrae.Nodulestendtooccurincropsandmaypersistfordaystomonthsaftertheonsetofacuterheumaticfever.第20頁(yè)/共77頁(yè)OtherclinicalfeaturesVariablefeverTirednesspalenessPneumoniaNosebleedsweatingAbdominalangina第21頁(yè)/共77頁(yè)LaboratoryfindingsBloodroutinetest:WBC↑,mildanemiaAcutephasereactants:ESR↑,CRP↑IsolationofgroupAstreptococci(+)Serumantibodyagainstthespecificstrptococci:ASO↑,ASK↑,AH↑,anti-DNaseB↑Immunesystem:IgG↑,IgA↑,C3

↑ECG:P-Rinterval↑,seconddegreeAVBRoutineroentgenogramEchocardiography第22頁(yè)/共77頁(yè)

TheJonesCriteriaRevisedwithAdditionofWorldHealthOrganizationRecommendationsMajorCriteriaMinorCriteriaCarditisFeverPolyarthritis,migratoryArthralgiaErythemamarginatumincreasedacute-phasereactantsChoreaESR↑,CRP↑SubcutaneousnodulesProlongedP-Rinterval

PlusEvidenceofaprecedinggroupAstreptococcalinfection(culture,rapidantigen,antibodytitersrise/elevation,historyofscarletfever)★

twomajormanifestations+EvidenceofS.I(streptococcalinfection)★

onemajor+twominormanifestations+EvidenceofS.I第23頁(yè)/共77頁(yè)Fever,bodyweight↓,tirenessTachycardiaorarrhythmiasESR↑,CRP↑,neutrocyte↑,antibodytiter↑Dignosisofactiverheumaticfever第24頁(yè)/共77頁(yè)Differentialdiagnosis

Fever

Carditis

Arthritis第25頁(yè)/共77頁(yè)DifferentialdiagnosisofcarditisInfectiveendocarditis:

anemia,splenomegaly,petechia,embolismbloodculture(+)vegetationsonendocardium/valvesViralmyocarditis:

arrhythmias(prematurecontraction)evidenceofviralinfection

第26頁(yè)/共77頁(yè)DifferentialdiagnosisofarthritisSystemiclupuserythematosus(SLE):

malarrash,proteinuria,hypertension,leukopenia,Coombs(+)hemolyticanemia,antinuclearantibodies(+)Juvenilerheumatoidarthritis(JRA):

morningstiffness,iridocyclitis,progressionofjointdestruction,ANA(+),rheumatoidfactor(+)第27頁(yè)/共77頁(yè)Bedrest

antibiotics

anti-rheumatismtherapy

heteropathyManagement第28頁(yè)/共77頁(yè)(1)Bedrest

carditiscardiamegalycongestiveheartfailure------2w2w+----4w4w++--6w6w+++8w3mon第29頁(yè)/共77頁(yè)(2)antibioticsProcainepenicillinG:

4.8millonU~9.6millonU/d,ivdrip×2~3w

PG

AST(+):

Erythromycinp.o×10d(3)anti-rheumatismtherapyCarditis:Prednisone,2mg/kg.d(≤60mg/d)×2~4w;reducedosegradually;fullduration=8~12warthritis:Aspirin,80~100mg/kg.d(≤3g/d)untilremission;graduallyreducetohalfdosefor4~6w第30頁(yè)/共77頁(yè)(4)heteropathy

congestiveheartfailure:steroid;oxygentherapy;diuresis;captopril;digitalis(smalldose)chorea:tranquilizer(chlorpromazine,barbital)

arthralgia:

immobilizationofaffectedjoints第31頁(yè)/共77頁(yè)prophylaxis

Recurrentrheumaticfever

benzathinePenicillin:1.2millionU,Q4W,≥5yearspatientswithestablishedheartdiseasemaycontinuefor≥10years,eventhewholelife.PG

AST(+):

Erythromycinp.o×6~7d,everymonth

BacterialEndocarditis

Patientswithrheumaticheartdiseaseshouldreceiveantibioticprophylaxisbeforeandafteroperationtopreventbacterialinfection.第32頁(yè)/共77頁(yè)EmphasesFivemajorclinicalmanifestationsJonescriteriaFeaturesofactiverheumaticfevertreatment:prophylaxis:long-actingPG第33頁(yè)/共77頁(yè)Kawasakidisease(Mucocutaneouslymphnodesyndrome)川崎病第34頁(yè)/共77頁(yè)教學(xué)目的與要求了解:病因;病理分期熟悉:輔助檢查;預(yù)后掌握:臨床表現(xiàn);診斷;

治療原則第35頁(yè)/共77頁(yè)

TomisakuKawasakidescribedKDin1967

KDisaacutegeneralizedsystemicvasculitisofunknownetiologywithfeverandrashes.CoronaryarterydilationoraneurysmsKDhasreplacedacuterheumaticfeverasthemostcommoncauseofacquiredheartdiseaseinchildrenIndevelopedcountries第36頁(yè)/共77頁(yè)Age:<4

yearsold(80%)<2

yearsold(50%)Sex:moreofteninmalesthaninfemales(1.5:1)Season:clustersinwinter/spring

Racialbackground:Asianchildren,especiallythoseofJapanesedescent.Epidemiology第37頁(yè)/共77頁(yè)EtiologyandPathogenesis

etiologyofKDremainsundiscovered.immunopathogenicmechanismforcoronarydiseaseorganismsuper-antigen

mimicantigen(HSP65)Tcell-mediatedimmuneresponsecytokine–mediatedimmunedamage第38頁(yè)/共77頁(yè)stageⅠ:1~10d,acutesmallperiarteritis;cardiacinflammatorychangesstageⅡ:10~25

d,coronaryarteritis;elasticlaminaeandmuscularlayerssplit,leadingtothrombusandaneurysms.stageⅢ:26~31

d,acuteinflammationremission;fibroustissueproliferates;intimathickens;coronaryarteriesnarroworocclude.stageⅣ:≧40d,cicatrizationinmyocardium;

occludedarteriesreopen.Pathophysiology

—systemicvasculitis(coronaryarteries)第39頁(yè)/共77頁(yè)normal

coronaryartery

stageⅠstageⅡ第40頁(yè)/共77頁(yè)10daysaftertheonsetofsymptoms,elasticlaminaesplits,intimaproliferatesandthickensinbranchofcoronaryartery.

第41頁(yè)/共77頁(yè)Hugecoronaryarteryaneurysm第42頁(yè)/共77頁(yè)Clinicalmanifestation

Mucocutaneouslymphnodeabnormalities

Cardiovascularabnormalities

Othernonspecificallymanifestations第43頁(yè)/共77頁(yè)Mainclinicalfeatures1.Feverusuallymorethan39°C,foratleast5daysHighspikingandremittentnotrespondstoantibioticsGenerallypersists1-2weekswithouttreatmentusuallyresolvesin1-2daysaftertreatmentwithintravenousgammaglobulin(IVIG)第44頁(yè)/共77頁(yè)2.BilateralconjunctivainjectionwithoutexudateMainclinicalfeatures第45頁(yè)/共77頁(yè)Mainclinicalfeatures3.inflammationofthelipsandoralcavityInjected,dry,fissured-lipsinjectedoralandpharyngealmucosaStrawberrytonguewithprominentpapillaeanderythemanooralexudates,ulcerations,orKoplikspots第46頁(yè)/共77頁(yè)Mainclinicalfeatures4.HandsandfeetErythema,orindurativeedemaofpalmsandsolesPeriungualmembranousdesquamationoffingersandtoesabout2weeksafteronsetTransversegroovesacrossthenails第47頁(yè)/共77頁(yè)Mainclinicalfeatures5.rashofvariousformsdiffuse,scarlatiniformorerythemapolymorphousrasherythemaordesquamationinperinealregion第48頁(yè)/共77頁(yè)Mainclinicalfeatures6.non-purulentcervicallymphadenopathy50-75%ofpatientsWithanodesizeof1.5cmorgreaterindiametertenderness,notred第49頁(yè)/共77頁(yè)1.

carditisTachycardiaGalloprhythm

systolicmurmursArrhythmia2.myocardialischemia

anginamyocardialinfarctionCardiovascularabnormalities第50頁(yè)/共77頁(yè)3.Coronaryarterialchanges

—2~4weeksafteronset/convalescent

phase

coronaryarteritisvesselintimaroughened

coronaryarteriesnarrow

coronaryarteriesdilation

coronaryarteryaneurysm第51頁(yè)/共77頁(yè)冠狀動(dòng)脈瘤(CoronaryArteryAneurysm)最早于發(fā)病第6天檢出,8~12周明顯急性期發(fā)生率最高為25~30%,恢復(fù)期發(fā)生率10~20%。急性期一過性冠狀動(dòng)脈擴(kuò)大(46%)持續(xù)性冠狀動(dòng)脈瘤(21%):多數(shù)1~2年內(nèi)恢復(fù),約5-6%不恢復(fù)。主要累及冠狀動(dòng)脈主干近端

第52頁(yè)/共77頁(yè)Aneurysmatleftanteriordescending(LAD)coronaryarteryLADCoronaryArteryAneurysm

20~30%ofuntreatedchildren冠狀動(dòng)脈瘤發(fā)生率:左前降支>左冠狀動(dòng)脈主干、右冠狀動(dòng)脈>左回旋支左回旋支第53頁(yè)/共77頁(yè)HighriskfactorsofCAaneurysm

age:<6monthor>3yearsmalesexfeverformorethan16daysorrecurrencecardiomegalyorarrhythmialabfindings:

Hb<80g/L,WBC>16~30X109/L,PLT>1000X109/L,ESR>100mm/hKDrecurrence第54頁(yè)/共77頁(yè)Less-commonfeatures

asepticmeningitisabdominalpainotitismediajaundicediarrhea

gallbladderhydropshepaticdysfunctionarthralgiaarthritisurethritis第55頁(yè)/共77頁(yè)Bloodanalysis:

WBC↑;mildanemia;PLT↑in2nd~3thweek;

ESR↑;

CRP↑;

ALT↑;AST↑

Laboratoryfindings第56頁(yè)/共77頁(yè)Immunesystem

IgG、IgM、IgA、IgE↑;

CirculatingImmuneComplexes

↑;C3

normalor↑第57頁(yè)/共77頁(yè)ECG:ST-T

abnormalitiesofpericarditisormyocardialinfarction

非特異性ST-T變化;心律失常;心包炎時(shí)廣泛ST段抬高、低電壓;心肌梗死時(shí)ST段明顯抬高、T波倒置、病理性Q波;Chestroentgenogram:nonspecificperihilarorparenchymainfiltrates;

cardiamegaly.第58頁(yè)/共77頁(yè)Echocardiography

coronaryarteritisintimaroughened

coronaryarteriesnarrowordilation

coronaryarteryaneurysm

pericardialeffusion

mitral,aortic,ortricuspiddisturbedflowcoronaryarteryaneurysmrightcoronaryarterytrunkaorta第59頁(yè)/共77頁(yè)

冠狀動(dòng)脈擴(kuò)張:

冠狀動(dòng)脈內(nèi)徑>正常范圍冠狀動(dòng)脈內(nèi)徑與主動(dòng)脈根部?jī)?nèi)徑之比>0.3

正常冠狀動(dòng)脈主干內(nèi)徑

0~3歲<2.5mm3~

9歲

<3mm9~

14歲<3.5mm

冠狀動(dòng)脈擴(kuò)張的分級(jí)輕度3mm<冠狀A(yù)直徑≤4mm

中度4mm<冠狀A(yù)直徑≤7mm

重度冠狀A(yù)直徑≥8mm(冠狀動(dòng)脈瘤)第60頁(yè)/共77頁(yè)Coronaryangiography

—myocardialischemia/multiplecoronaryaneurysmsnormalaneurysmLADdilationandnarrow第61頁(yè)/共77頁(yè)Diagnosticguidelines

(fortypicalcases)feverlastingmorethan5days+4ofthefollowing5criteria(otherillnessesmustbeexcluded):

1.polymorphousrash2.bilateralconjunctivalinjectionwithoutexudatediffuseinjectionoforalmucosa,erythemaorfissuringofthelips,strawberrytongue4.nonpurulentcervicallymphnodeenlargement(onelymphnode>1.5cm)5.extremitychanges:erythemaofpalms/soles,indurativeedemaofhands/feet,Membranousdesquamationofthefingertips第62頁(yè)/共77頁(yè)Diagnosticguidelines

(foratypicalcases)feverlastingmorethan5days

≤3ofthe5criteria

coronaryarteriesdilationoraneurysmdetectedbyechocardiography

第63頁(yè)/共77頁(yè)DifferentialdiagnosisScarletfever

Redrashblancheswithpressure,whichisdiffusebutsparesthepalms,soles,andface.Thefaceappearsflushed.Theskinrashfadesinaweekandisfollowedbyextensivedesquamation.PatienthasgoodresponsetoPG.第64頁(yè)/共77頁(yè)DifferentialdiagnosisExudativeandErythemaMultiforme

polymorphousErythema,herpesandextensivedesquamation;oralulcers;conjunctivalexudate;noindurativeedemaofpalmsorsoles第65頁(yè)/共77頁(yè)

relievevasculitisinhibitPLTaggregationTreatment&Medication第66頁(yè)/共77頁(yè)(1)aspirin

administeredforanti-inflammatoryandantithromboticeffects

acutephase:30-100mg/kg/dPOintid/qid72hafterdefervescence:reducedosegradually2weeksafterdefervescence:3-5mg/kg/dp.o×6~8weeksuntilESR,PLTandcoronaryarteriesreturntonormal(?<3mm)第67頁(yè)/共77頁(yè)reducetheprevalenceofcoronaryabnormalitiesandleadtorapi

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

評(píng)論

0/150

提交評(píng)論